3 Overlooked Stocks Set to Soar in 2026

Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors.

Axsome Therapeutics (NASDAQ: AXSM) is a mid-cap with only three approved therapies, while small-cap stock NovoCure (NASDAQ: NVCR) has approvals in four indications for its Tumor Treating Fields, and small-cap MBX Biosciences (NASDAQ: MBX) has several late-stage therapies in its pipeline. I like their potential and believe the markets haven't fully digested recent positive news for the trio.

Here's why I think each of these stocks could soar in 2026.

Source Fool.com